...
首页> 外文期刊>SIAM journal on applied dynamical systems >Upregulation of long noncoding RNA PEG10 associates with poor prognosis in diffuse large B cell lymphoma with facilitating tumorigenicity
【24h】

Upregulation of long noncoding RNA PEG10 associates with poor prognosis in diffuse large B cell lymphoma with facilitating tumorigenicity

机译:长度非划分RNA PEG10的上调性与促进致瘤性的弥漫性大B细胞淋巴瘤预后差

获取原文
获取原文并翻译 | 示例
           

摘要

Diffuse large B cell lymphoma (DLBCL) is one of the most common malignancies worldwide. To date, there has been little progress in improving the overall survival of DLBCL patients. Emerging evidences have implicated that long noncoding RNAs (lncRNAs) have important regulatory roles in fundamental biological processes, and some of them are involved in cancer initiation, development and progression. This study was to investigate the expression of lncRNA PEG10 in a cohort of DLBCL patients to assess its clinical value and biological function in DLBCL. We first found that the expression of PEG10 was upregulated in DLBCL tumorous tissues and that cell lines compared with the normal. Moreover, we illustrated that PEG10 was significantly correlated with B symptoms, IPI score, CHOP-like treatment and rituximab. In addition, ROCAUC of PEG10 was up to 0.8228, implicating that PEG10 could be a diagnostic marker for distinguishing DLBCL from normal. Importantly, we verified that PEG10 was a key independent predictive factor for DLBCL prognosis from sizable samples through the longtime follow-ups. Furthermore, we revealed that knockdown of PEG10 expression by siRNA could lead to growth arrest and cell apoptosis in vitro. Our results suggested that PEG10 could represent a novel indicator of poor prognosis and might be served as a potential target for the diagnosis and gene therapy of DLBCL.
机译:弥漫性大B细胞淋巴瘤(DLBCL)是全球最常见的恶性肿瘤之一。迄今为止,提高DLBCL患者的整体存活率几乎没有进展。新兴的证据涉及到很长的非编码RNA(LNCRNA)在基本生物过程中具有重要的监管作用,其中一些人参与癌症启动,发展和进展。该研究是探讨LNCRNA PEG10在DLBCL患者队列中的表达,以评估DLBCL中的临床价值和生物学功能。我们首先发现PEG10的表达在DLBCL肿瘤组织中上调,与正常相比细胞系。此外,我们说明PEG10与B症状显着相关,IPI评分,切碎的处理和Rituximab。此外,PEG10的rocaUC高达0.8228,暗示PEG10可以是用于区分DLBCL的诊断标记。重要的是,我们核实PEG10是通过长期随访的大型样本的DLBCL预测的关键独立预测因素。此外,我们透露,siRNA的PEG10表达的敲低可能导致体外生长停滞和细胞凋亡。我们的结果表明,PEG10可以代表一种预后不良的新指标,并且可以作为DLBCL诊断和基因治疗的潜在目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号